|
Originally published In Press as doi:10.1074/jbc.M207551200 on September 23, 2002
J. Biol. Chem., Vol. 277, Issue 51, 49911-49920, December 20, 2002
Simultaneous Determination of Low Free
Mg2+ and pH in Human Sickle Cells using 31P NMR
Spectroscopy*,
James P.
Willcocks ,
Peter J.
Mulquiney§,
J. Clive
Ellory¶,
Richard L.
Veech ,
George K.
Radda, and
Kieran
Clarke**
From the Departments of Biochemistry and ¶ Physiology,
University of Oxford, South Parks Road, Oxford OX1 3QU,
United Kingdom, and the National Institute on Alcohol Abuse and
Alcoholism, Rockville, Maryland 20852
Received for publication, July 26, 2002, and in revised form, September 11, 2002
 |
ABSTRACT |
The concentrations of free magnesium,
[Mg2+]free, [H+], and
[ATP] are important in the dehydration of red blood cells from
patients with sickle cell anemia, but they are not easily measured.
Consequently, we have developed a rapid, noninvasive NMR spectroscopic
method using the phosphorus chemical shifts of ATP and
2,3-diphosphoglycerate (DPG) to determine
[Mg2+]free and pHi
simultaneously in fully oxygenated whole blood. The method employs
theoretical equations expressing the observed chemical shift as a
function of pH, K+, and
[Mg2+]free, over a pH range of 5.75-8.5 and
[Mg2+]free range 0-5 mM. The
equations were adjusted to allow for the binding of hemoglobin to ATP
and DPG, which required knowledge of the intracellular concentrations
of ATP, DPG, K+, and hemoglobin. Normal oxygenated whole
blood (n = 33) had a pHi of
7.20 ± 0.02, a [Mg2+]free of 0.41 ± 0.03 mM, and [DPG] of 7.69 ± 0.47 mM. Under the same conditions, whole sickle blood
(n = 9) had normal [ATP] but significantly lower
pHi (7.10 ± 0.03) and
[Mg2+]free (0.32 ± 0.05 mM)
than normal red cells, whereas [DPG] (10.8 ± 1.2 mM) was significantly higher. Because total magnesium was normal in sickle cells, the lower [Mg2+]free
could be attributed to increased [DPG] and therefore greater magnesium binding capacity of sickle cells.
 |
INTRODUCTION |
Magnesium is the second most abundant intracellular cation after
potassium and is important in the regulation of more than 300 enzymes
(1-3) and ion transport across cell membranes (4, 5). Some diseases,
such as hypertension, pre-eclampsia, and sickle cell anemia exhibit
pathologies linked to low magnesium levels (6-8). The genetic defect
in sickle cell anemia results in the synthesis of an abnormal hemoglobin (Hb) subunit, which polymerizes upon deoxygenation. This
polymerization produces the characteristic sickle deformation in red
blood cells and leads to microcirculatory occlusion and consequent
tissue ischemia. Sickling depends strongly on the intracellular Hb
concentration (9) and is enhanced by dehydration of erythrocytes, a
process involving potassium and sodium transport across cell membranes, which is in turn thought to be regulated by cytosolic free magnesium, [Mg2+]free,1
via the KCl cotransporter (KCC1) (5, 10). Thus dehydration of sickle
cells, and thereby the process of sickling, may be controlled by
changes in the magnesium content (8, 11).
To assess its role in sickle cell anemia, an accurate and reproducible
method was required for the measurement of
[Mg2+]free. Although several methods have
been developed to determine [Mg2+]free in red
blood cells, such as null point titration with metallochromic dyes
(12), magnesium-sensitive electrodes (13, 14), use of divalent cation
ionophores (15), and 31P NMR spectroscopy (16, 17), the
reported values vary 3-fold, from 0.2 to 0.6 mM (18-20).
Of these methods, the one noninvasive technique that has been used
extensively is that of 31P NMR spectroscopy (16-19,
21-25). However, there are a number of potential errors associated
with using the observed NMR signal to determine
[Mg2+]free, including uncertainty in the
binding constant between ATP and magnesium (26), the effect of
intracellular ionic content on this interaction (27), and the effect of
metabolite-Hb interactions (23). Gupta and co-workers (2), the first to
use this method, addressed the first two problems by determining an
apparent MgATP binding constant,
K(app)bMgATP, from the
difference between the end points of the chemical shifts of the
magnesium bound and unbound and phosphorus nuclei of ATP,
  -MgATP and   -ATP. This
decreased the number of equilibria that had to be considered and
overcame the need to rely on adjusted published values of
K(app)b, which varied 100-fold (28). However, as with any simplification, problems are associated with this
approach, which include the possible difference in ionic strength
between solutions and in vivo conditions, the accuracy of
the chemical shift end points required to determine
K(app)b (29), and the assumption that
 -ATP did not vary.
Because the chemical shifts of 31P NMR phosphorus peaks
depend on many different factors (30), accurate analysis should take all factors into account, which has become possible with the increased capacity of computation. Previous analyses using phosphorus chemical shifts have been used to obtain either pH (24) or
[Mg2+]free (16) in red blood cells. Only one
approach used the 31P resonances of ATP to determine
both pH and [Mg2+]free (31), but
this averaged all ATP species with an apparent binding constant and
made no allowance for the effect of Hb and K+ binding
upon the observed chemical shift. It is possible that metabolite
relaxation times become so long upon binding to Hb that such species do
not contribute to the observed NMR peak, making them
"NMR-invisible," and hence they could be omitted from analysis.
Therefore, the effect of Hb on metabolite NMR "visibility" was
investigated here. In addition, standard titration curves of ATP and
DPG phosphorus chemical shifts were expressed in equations as functions
of pH and [Mg2+]free. Adjusting
these equations for Hb and K+ binding to ATP and DPG
improved the method for measuring pH and [Mg2+]free in red blood cells. This newly
developed NMR-based analysis allowed the simultaneous determination,
for the first time, of the intracellular pH and
[Mg2+]free in normal and sickle blood.
Preliminary reports of this work have been published in abstract form
(32, 33).
 |
EXPERIMENTAL PROCEDURES |
Preparation of Standard Solutions for Titration
Curves--
Solutions were prepared as described previously (34) and
contained 5 mM each K2ATP:2H2O,
Na5DPG:3.5H2O (Sigma), and Pi
(British Drug House, Poole), at 310.15 K and an ionic strength of 0.25. The pH of the solutions ranged from 5.75 to 8.50, and the total magnesium varied from 0 to 15.9 mM. Ionic strength was
adjusted to 0.25 by adding KCl, and the pH was adjusted using 1 M KOH or HCl. In total, 130 samples were prepared, with 13 pH values, at 10 [Mg2+]free concentrations.
Using the relevant equilibrium constants (Table I) for each particular ionic
species, the amount of total MgCl2, [Mg]T,
added to achieve a desired [Mg2+]free was
calculated using the Equation 1,
View this table:
[in this window]
[in a new window]
|
Table I
Acid dissociation constants (upper section) and equilibrium constants
(lower section) at 37 °C, I = 0.25 and K+ = 0.2 used in
Equation 2 to generate the required amounts of [Mg]T for the
titration solutions
|
|
|
(Eq. 1)
|
where f is a ratio of the ionized ligand,
Az , to the total ligand, AT.
|
(Eq. 2)
|
For the calibration solutions containing the three magnesium
binding ligands, ATP, DPG, and Pi, the [Mg]T
required for each solution was calculated from Equation 3.
|
(Eq. 3)
|
The solution of Equation 3 and the simultaneous equations
involved in providing the correct ionic strength and pH (see Appendix I) were achieved using MathematicaTM (Wolfram Research, Champaign, IL).
Using this method, MgCl2 was added to give solutions
containing [Mg2+]free of 0, 0.05, 0.10, 0.25, 0.50, 0.75, 1.00, 1.25, 2.50, and 5.00 mM.
31P NMR Spectroscopic Analysis of Standard
Solutions--
31P NMR spectra of the solutions were
acquired using a 9.4-tesla, Oxford Instruments wide bore
superconducting magnet interfaced with a Varian Inova spectrometer
operating at a phosphorus frequency of 161.9 MHz. A 10-mm probe was
used, with the sample temperature set to 310.15 K. The homogeneity of
the magnetic field was optimized by shimming on the 1H free
induction decay to give 1H spectral line widths of 9 ± 2 Hz. For each sample, a 90o pulse (18.5 µs) was used
with an interpulse delay of 15 s, a spectral width of 8 kHz, and
no proton decoupling. The delay time was based on preliminary
experiments in which T1 values were determined for sample solutions by
running a preinstalled macro on the Varian spectrometer, using a
standard inversion recovery method. Each spectrum consisted of 128 summed transients. Up to 256 transients were acquired for samples in
which the -phosphorus of ATP was especially broad.
A capillary containing ~50 µl of 0.5 M phenylphosphonic
acid was used as an external chemical shift reference, standardized relative to phosphocreatine at 0.00 ppm. Prior to Fourier
transformation, the signal:noise ratio was increased by multiplying the
31P NMR free induction decays by an exponential function
sufficient to generate a line broadening of 1 Hz, and the time domain
signals were zero filled once. The NMR1 program (Tripos, St. Louis, MO) was used to fit peak areas, line widths, and chemical shifts of spectral resonances.
Theoretical Fitting of the Observed Chemical Shifts--
The
chemical shifts for the 3-phosphorus of DPG and -phosphorus of ATP
peaks were plotted against pH and [Mg2+]free,
generating a three-dimensional surface. This was then fitted to an
equation using the nonlinear fit algorithm in MathematicaTM with the
main parameters being the chemical shifts of the H+,
K+, and Mg2+ bound forms of -ATP and 3P-DPG,
and the binding constants of each species to H+,
K+, and Mg2+.
The equation used for fitting was based on the principle that the
observed chemical shift ( obs) could be described by
combining the chemical shifts of all of the relevant forms of a
substance present in the equilibrium and weighting their contribution
to the observed chemical shift according to the ratio of their
population to that of the total substance present (35).
|
(Eq. 4)
|
Hence for ATP, assuming all ATP to consist of several
species,
|
(Eq. 5)
|
the theoretical chemical shift can be described by
Equation 6.
|
(Eq. 6)
|
Using the equilibrium constants (assuming activity coefficients
of unity), the concentrations of all forms can be expressed relative to
the concentration of the completely ionized form (f values).
Taking these and substituting in the above equation, the observed
chemical shift is represented by Equation 7.
|
(Eq. 7)
|
Similarly for DPG, the following equation
describing the observed chemical shift for DPG was formulated, assuming
the forms present were DPG5 , HDPG4 ,
H2DPG3 , MgDPG3 ,
MgHDPG2 , KDPG4 , and
KHDPG3 .
|
(Eq. 8)
|
The substitution of [H+] to 10 pH was
used to make the equations more convenient. "Goodness" of fit may
be determined by 2, where
|
(Eq. 9)
|
with Fi the value of the ith
data point, and fi is the value obtained from
the fit.
Model of the Red Blood Cell--
The chemical shifts of the
intermediate species were calculated from the above fitting equations
and were used in new multiple equilibria equations, which included the
binding of Hb to ATP4 , MgATP2 , and
DPG5 . To achieve this, it was assumed that the chemical
shifts of each species were not affected by binding to Hb (2, 14). Binding constants for Hb were taken from Berger et al. (36), where KbHbATP is 360 M 1, KbHbMgATP is 39 M 1, and KbHbDPG is 250 M 1.
Therefore,
|
(Eq. 10)
|
|
(Eq. 11)
|
The above equations are simplified from the MathematicaTM
program presented in Appendix II.
After determination of chemical shifts of the -phosphate peak of ATP
( ) and the phosphate on the 3 carbon of DPG
( 3P) from acquired spectra of red blood cells, these
equations were solved simultaneously to calculate pH and
[Mg2+]free in red blood cells using the Solve
algorithm in Mathematica (Appendix II). A requirement of this method is
that the total amounts of ATP, DPG, Hb, and K+ must be
entered in the algorithm before a solution can be found. ATP and DPG
concentrations were assayed as described below, and Hb and
K+ concentrations (mmol/liter cell water) were assumed to
be 7 mM (2, 37) and 160 mM (38), respectively.
Erythrocyte total magnesium was calculated by summing the
concentrations of all magnesium-containing species, determined from the
solution of this algorithm, for comparison with the total magnesium
determined using a standard colorimetric assay (see later).
Preparation of Whole Human Blood Samples--
This study was
approved by the Ethics Committee, Medical School, University
of Birmingham. Blood from volunteers (8-10 ml) or from
consenting homozygous sickle cell disease (HbSS) patients (5 ml)
was collected by venipuncture into lithium-heparinized syringes. To
simulate in vivo fully oxygenated blood, whole blood samples
were prepared for analysis by equilibration with a mixture of
O2 and CO2 (95%:5%), adjusted to give a final
PCO2 of 40 mmHg and PO2 between 200 and 400 mmHg, determined using a blood gas analyzer (Radiometer ABL 330). The
PO2, PCO2, and
pHex were measured before and after NMR analysis, at which
time the PO2 remained > 150 mm Hg, to
ensure complete oxygenation at all times during analysis. To minimize
cell degradation, time from phlebotomy to analysis was kept to a
minimum (1-3 h), during which blood samples were stored on ice.
Separation of Sickle Cells by Density--
Sickle cells are
heterogeneous with respect to total magnesium, DPG content, and pH (39,
40), which vary with cell density as the cell sickles, therefore we
separated sickle cells into three fractions using a discontinuous
arabinogalactose density gradient before analysis,
thereby allowing comparison with unfractionated whole sickle blood.
Cells were fractionated on discontinuous density gradients of Stractan
II (arabinogalactan) as described previously (41) with minor
modifications (42).2 All
separations were performed at 4 °C in a cold room to maintain ATP
concentrations. Briefly, two iso-osmotic Stractan density layers, 1.090 and 1.099 g/ml, were used with a cushion of 1.196 g/ml. Blood (20 ml)
was collected from six consenting HbSS patients, unmatched for blood
antigen type (one with blood group A, one with blood group O, and four
with blood group B). Following centrifugation at 3,000 × g for 10 min, plasma was removed and stored on ice, and the
buffy coat was carefully removed and discarded. Each of the six packed
blood cell samples was washed twice with ice-cold buffer containing 5 mM KCl, 145 mM NaCl, 0.05 mM EGTA,
0.2 mM MgCl2, 10 mM Na-HEPES, pH
7.4. For each experiment, cells from two patients were pooled to give a
total of 8-10 ml of packed cells, which
were layered on the Stractan
gradient. After ultracentrifugation, three lay-ers were harvested,
light (d < 1.090 g/ml), medium (1.090 g/ml < d < 1.099 g/ml), and dense (d > 1.099 g/ml), with the dense layer containing most of the irreversibly sickled
cells. The density-fractionated red cells were washed three times at
4 °C, using the above buffer, before being resuspended in pooled,
heparinized plasma from the same two patients, to give final
hematocrits of 35-50%. Normal ATP concentrations (see later) and
microscopic observation at high magnification showed that no
agglutination occurred in the pooled, unmatched blood samples, possibly
because of the high heparin concentrations (43). The "whole blood"
samples were prepared for NMR analyses as described above. The time
taken from phlebotomy to NMR analyses was 5-7 h.
31P NMR Spectroscopy of Human Red Blood
Cells--
31P NMR spectra of the cells were acquired
using the magnet and spectrometer described above. The fully oxygenated
whole blood (~ 4.5 ml), prepared as above, was sealed in a 10-mm NMR
sample tube together with an external reference capillary containing 50 µl of 0.3 M phenylphosphonic acid and brought to 37 °C
before 31P NMR spectroscopic analysis in a 10-mm probe. The
probe temperature was set to 310.15, the samples were not spun, and no
proton decoupling was used. The homogeneity of the magnetic field was
optimized by shimming on the 1H free induction decay to a
line width of 30 ± 2 Hz (normal cells) or 23 ± 2 Hz (sickle
cells). A 45° pulse was used with an interpulse delay of 0.52 s
to give peaks of a high signal:noise ratio (25). The spectral width was
8 kHz, with an acquisition time of 0.272 s (4,500 data points),
and 2048 transients were summed. The samples were at 37 °C for a
maximum of 38 min. Prior to Fourier transformation, the signal:noise
ratio was increased by multiplying the 31P NMR free
induction decays by an exponential function sufficient to generate a
line broadening of 7 Hz, and the time domain signals were zero filled
once, giving a digital resolution of 1.1 Hz/point. The NMR1 program was
used to fit peak areas, line widths, and chemical shifts of spectral resonances.
Chemical Assays--
Immediately after the NMR measurement, the
blood was poured from the NMR tube and samples taken for light
microscopy to count the number of sickled cells, and for determination
of hematocrit and ATP and DPG concentrations using diagnostic kits
(Sigma). Total magnesium concentrations in plasma and trichloroacetic
acid extracts of whole blood were determined in duplicate using
diagnostic kits (Sigma). The total erythrocyte magnesium concentrations
were then calculated by subtracting the plasma total magnesium from the
whole blood measurement. Concentrations are presented per liter of cell
water, assuming a 95% packing efficiency and 70% cellular water
content for normal cells, 66% for whole sickle blood, and 65 and 62%
for medium and dense sickle cells, respectively (37). The hematocrits
were determined after centrifugation at 13,000 × g for
10 min in a microhematocrit centrifuge using a Hawksley microhematocrit
reader, with all measurements made in triplicate.
Effect of Hb on ATP and DPG NMR Visibility--
To alleviate
concerns that metabolites bound to Hb would be NMR-invisible, solutions
were prepared containing 2 mM
K2ATP:2H2O, 7 mM
Na5DPG:3.5H2O (Sigma), 190 mM KCl,
3 mM MgCl2:6H2O with and without 6 mM human Hb (Sigma), and the pH was adjusted to 7.2 at
37 °C using 1 M KOH or HCl. 31P NMR spectra
of the solutions were acquired as described above. Immediately after
the NMR measurement, ATP and DPG concentrations were determined as
described above.
Statistics--
Data are presented as means ± S.D.
Significance was tested using analysis of variance, with repeated
measures where appropriate, with p < 0.05 considered significant.
 |
RESULTS |
Typical 31P NMR spectra of the titration solutions
acquired between a pH 6 of 8 and [Mg2+]free
between 0 and 5 mM are shown in Fig.
1. The ATP, DPG, and Pi peaks
increased in chemical shift as pH increased, reflecting a decrease in
electronic shielding upon proton association. The maximal chemical
shift changes are given in Table II.
Increasing [Mg2+]free altered the of all
ATP peaks ( (3.26 ppm) and (3.72 ppm) more than (0.46 ppm))
but led to only slight changes in those of Pi (0.03 ppm)
and 3P- and 2P-DPG (0.34 and 0.76 ppm, respectively). The chemical
shifts of the 2P-DPG and Pi peaks were more sensitive to
changes in pH than to changes in magnesium (3.15 and 2.35 ppm,
respectively), whereas those of the - and -phosphate peaks of ATP
were equally sensitive to both pH and [Mg2+]free. At the physiological pH of 7.2 and [Mg2+]free of 0.3 mM, the
-ATP triplet could not be fully resolved because of line broadening
caused by chemical exchange, but the peak could still be used for
chemical shift determination. The Pi peak overlapped with
the 2P-DPG doublet, thus neither could be used for pH or
[Mg2+]free determination in red blood cells.
Instead, it was necessary to use the 3P-DPG peak.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 1.
Spectra of the standard solutions over the pH
range 5.75-8.5 and [Mg2+]free concentrations
0-5 mM. A spectrum typically expected for blood at
physiological conditions of a pH of 7.2 and
[Mg2+]free 0.3 mM is
central.
|
|
Three-dimensional Curves from the Chemical Shifts of -Phosphate
of ATP and 3-Phosphate of DPG--
Using the observed -ATP peak
chemical shifts ( ), a three-dimensional surface curve
was generated as a plot of pH and [Mg2+]free
with the section relevant to physiological conditions expanded (Fig. 2a). Equation 7 was
fitted to these data and plotted in Fig. 2b. Using the
observed 3P-DPG peak chemical shifts ( 3P), a
three-dimensional surface curve was generated as a plot of pH and
[Mg2+]free (Fig.
3a). Equation 8 was fitted to
these data and plotted in Fig. 3b. The final values of the
fitting parameters of chemical shifts and explicit equilibrium
constants are given in Table III.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
Plot of the observed chemical shift
(a) and the curve produced by the fitting equation
(b) of the chemical shift of
-ATP against pH and
[Mg2+]free, expanded to show the
physiological region.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
Plot of the observed chemical shift
(a) and the curve produced by the fitting equation
(b) of the chemical shift of 3P-DPG against pH and
[Mg2+]free.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Parameters used to produce the best fit of the theoretical chemical
shift to that of the observed, including interactions with potassium
Equilibrium constants are explicit binding constants at 37 °C and
I = 0.25. Chemical shifts are presented as ppm relative
to phosphocreatine at 0 ppm. Errors are presented as standard errors.
|
|
Effect of Hb on ATP and DPG NMR Visibility--
The line widths of
DPG and ATP peaks each increased by 60% on addition of Hb ( -LW from
28 to 45 Hz, and -LW from 50 to 80 Hz). Despite this, when the
normalized peak integral was divided by the assayed total metabolite
concentration, the values changed by less than 3% on addition of Hb.
This indicated that ATP and DPG NMR visibility was not significantly
impaired by binding to Hb, in that the Hb-bound component of the
observed chemical shift was not so broad as to be lost in the noise of
the spectrum.
Fig. 4 shows a typical 31P
NMR spectrum of normal red blood cells. The DPG peaks were relatively
sharp (LW 20 Hz), whereas the line width of the phosphate of
the ATP peak was significantly greater than the line widths of the
other ATP peaks ( -LW 65 Hz, -LW 35 Hz). Using the 3P-DPG
and -ATP phosphate peak chemical shifts, the intracellular pH and
[Mg2+]free were determined simultaneously
using the values of ATP and DPG determined by enzymatic analysis.
Analysis of Normal and Sickle Red Blood Cells--
Fractionation
of the 8-10 ml of packed sickle cells gave fraction volumes in the
approximate ratio 3:5:2 for light:medium:dense fractions. When
resuspended in their plasma, the hematocrits were in the range of
35-50%. Morphological microscopic examination, as estimated by
criteria described previously (42), revealed that the dense fraction
contained between 50 and 70% irreversibly sickled cells, the medium
contained ~5%, and the light had fewer than 1%.
The determined levels of DPG, ATP, pHi,
[Mg2+]free, and MgT, both
predicted using the model and assayed, are presented in Table IV for normal and sickle whole blood and
for each of the separated sickle cell fractions, light, medium, and
dense. DPG was elevated significantly in all three sickle cell
fractions, by a maximum of 2.4 mM in the medium density
fraction, compared with normal blood cell DPG of 7.7 mM.
However, the DPG concentration of the dense cells was significantly
lower than that of the other sickle cells, but not as low as the normal
cells. ATP was normal in all of the sickle cell samples. The
PCO2 of whole blood and cell fractions was set
to be the same for all the analyses, which gave normal blood a measured
pHex of 7.39 ± 0.03. However, at a
PCO2 of 40 mm Hg, the pHex of whole
sickle blood was 0.07 pH unit more acidic than normal blood. After
fractionation, the pHex of sickle cells was 0.23 pH unit
more acidic than whole control blood. The PO2 never dropped
below 150 mm Hg and usually was around 300 mm Hg. In parallel with
their more acidic pHex, the pHi of all sickle cell samples was 0.10-0.13 pH unit more acidic than normal cells. [Mg2+]free was decreased significantly by
~0.09 mM in the medium and the dense cells, and in the
whole sickle blood compared with normal cells. There was no change in
MgT, either predicted from the model or measured by
assay.
View this table:
[in this window]
[in a new window]
|
Table IV
ATP, DPG, pCO2, pHex, pHi,
[Mg2+]free, and total Mg concentrations (µmol/ml
intracellular water) in normal and sickle red blood cells
Data are presented as means ± S.D.
|
|
Thus, using this new method, which considered all significant
interactions between metabolites, H+, K+,
Mg2+, and Hb, oxygenated sickle blood had normal ATP
concentrations and significantly lower pHex,
pHi, and [Mg2+]free than normal
cells, both in the dense fractions after separation and as
unfractionated whole blood.
 |
DISCUSSION |
Less than 0.5% of body magnesium resides in blood plasma, and yet
plasma total magnesium is commonly used as a marker of body magnesium
status because of the absence of an easy reproducible method for
measuring [Mg2+]free. Because intracellular
[Mg2+]free is important in regulating
biochemical reactions, it may serve as a better marker of status, and,
of all tissues, red blood cells are the most readily available for
study in humans. The best method by which to measure
[Mg2+]free is frequently discussed, but the
effect of pH on [Mg2+]free measurements is
often not taken fully into account (27). Consequently, we have
developed a method to quantify both
[Mg2+]free and pH in red blood cells under a
wide range of conditions.
Observed Chemical Shift versus pH and
[Mg2+]free--
From the plot of the
chemical shift of 3P-DPG, it can be seen that 3P did not
significantly change with [Mg2+]free, other
than at high pH (>7.8) and very low
[Mg2+]free (<0.1 mM). This
suggested that 3P could be used as a good indicator of
physiological pH. The chemical shift of the phosphate of ATP
changed significantly with both pH and
[Mg2+]free in the physiological region to
allow an accurate determination of pH and
[Mg2+]free from the observed chemical shifts.
A change in chemical shift of ~0.05 ppm corresponded to a 0.015 mM change in [Mg2+]free at
constant pH.
The equations relating the observed chemical shift of 3P-DPG and
-ATP and to pH and Mg2+ accurately fitted both
experimental curves using the theoretical equations (Equations 7 and
8). These equations were solved simultaneously to determine both
intracellular pH and [Mg2+]free in normal and
sickle red blood cells (Table IV).
31P NMR studies (44) on the effects of Mg2+ on
ATP have shown that Mg2+ induces the greatest chemical
shift on the -phosphorus and the least on the -phosphorus
resonance of ATP. This has been interpreted as indicating that
Mg2+ binds mainly to the - and -phosphate groups (45,
46), possibly via a cyclic six-membered transition state that is
energetically favored (Fig. 5) and has
little interaction with the residue. Thus, previous studies have
used the changing difference of the chemical shift of the from the
resonance of ATP,   , to determine intracellular
[Mg2+]free in many tissue types (16, 47, 48)
and thereby use the -ATP peak as an internal chemical shift
standard. However, it was seen (Fig. 1) that the -phosphate chemical
shift was not only variable over the ranges of pH and magnesium
studied, but also -phosphorus and -phosphorus changed as pH and
magnesium were varied. Therefore, in this study, all chemical shifts
were measured relative to an external capillary standard.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 5.
Possible structure of MgATP2 ,
with Mg2+ bound in an energetically favored six-member
cyclic transition state.
|
|
Use of Explicit Equilibrium Constants--
One important new
aspect of this study was the use of explicit equilibrium constants as
opposed to apparent constants, which allows the ready adaptation of the
technique to a much wider range of conditions, either in red blood
cells or other tissues. However, it also necessitates that a greater
number of constants be accurate. This necessity was overcome in the
original method of Gupta et al. (16) by measuring an
apparent dissociation constant for MgATP,
K(app)dMgATP, under in
vitro conditions thought appropriate to the in vivo
situation. However, this had three major problems. First, the two
conditions would not have the same ionic strength, despite possessing
same concentration of K+. This is because of the presence
of other charged species, such as DPG, in the in vivo
environment, and therefore the measured K(app)dMgATP would also differ
between in vitro and in vivo conditions. For
example, the ionic strengths would have changed from 0.16 to 0.19 M as ATP and magnesium concentrations were varied in the
in vitro solutions. The addition of 7 mM DPG
would have increased the ionic strength to 0.24 M in
vivo. Assuming that K(app)dMgATP
was measured at 0.17 M ionic strength to be 38 mM, it would correspond to ~60 mM at this
in vivo ionic strength (adjusted using standard
thermodynamic equations (3)). Because the calculated
[Mg2+]free is directly proportional to
K(app)dMgATP this would have the
effect of also increasing [Mg2+]free by a
factor of 1.5. Second, an accurate assessment of
K(app)dMgATP from 31P NMR
requires an accurate knowledge of the chemical shift end points
ATP and MgATP. Although
ATP may be relatively straightforward to determine,
MgATP is more difficult because of the presence of the
Mg2ATP species, which would affect the overall observed chemical shift (29). Third, rather than absolute chemical shifts, the
difference between  -ATP and  -ATP
was used to determine K(app)dMgATP,
assuming that neither was particularly affected by pH near neutrality.
However, this is not the case at extreme magnesium levels where binding
constants are determined.
One further limitation of this approach, although it might, in theory,
alleviate the need to know the exact effect that intracellular ionic
content would have on binding interactions, is that it places restrictions on how readily the method can be applied under a range of
conditions. For each new intracellular condition, including a pH
change, a new apparent binding constant would have to be determined experimentally.
Effect of K+--
Different physiological conditions
may have different potassium concentrations. Changing
[K+] exerts not only an effect on
KbMgATP, because of changing the ionic strength,
but also an effect on the observed chemical shift by changing the
amount of potassium-bound species (27). By assuming KX and
KHX species existed for both DPG and ATP, a significant
improvement in the mathematical fit of the observed data occurred, with
2 decreasing by 50 and 90% for DPG and ATP curves,
respectively (data not shown). As a verification of this model, the new
value for the explicit MgATP2 binding constant of
7.50 × 104 M 1 was in
excellent agreement to that calculated by Mulquiney and Kuchel
(37), which approximated to 8.0 × 104
M 1 when adjusted for pH and ionic strength.
Effect of Hb on Metabolite NMR Visibility--
If the metabolite
relaxation times were sufficiently long when bound to Hb, the Hb-bound
component of the overall observed chemical shift would be broad enough
to be lost in spectral noise. Thus, Hb-bound metabolites would be
NMR-invisible and could be omitted from the analysis. However, we found
no loss in metabolite visibility on binding to Hb, so the effect of
oxygenated Hb binding must be included in the analysis of
[Mg2+]free. Furthermore, when the
concentration of ATP in red blood cells was estimated from the relative
peak integrals of ATP and DPG in the observed spectra using the assayed
concentration of DPG, there was less than a 10% variation between this
value and that of the spectrophotometrically measured ATP
concentration. This confirms the finding that DPG and ATP
remain NMR-visible when bound to Hb.
Effect of Hemoglobin Binding on
[Mg2+]free Analysis--
In the original
31P NMR method, the effect that metabolite-Hb interactions
had on the equilibria was considered (16). However, by 1983 (48), this
complexity in the method was lost, perhaps because, according to their
equilibrium constants, Hb bound MgATP and ATP equally strongly, which
would allow the Hb effect to be ignored (23). Also, this added
complexity, combined with the lack of computational power at the time,
perhaps made solving the necessary multiple equilibria too difficult to
be achieved routinely. A disregard of the effect of Hb has existed ever
since, until 1997 when the effect of metabolite-Hb interactions was
reevaluated (23).
The standard titration solutions did not include Hb because the extent
of DPG and ATP binding to Hb was uncertain, and its effect would
complicate the analysis of the important interactions among
H+, Mg2+, K+, ATP4 ,
and DPG5 . However, after the observed experimental
chemical shifts were modeled by equations describing the effect of all
intermediates as functions of H+ and Mg2+,
these equations were altered to allow for Hb binding (Equations 10 and
11). Although each equilibrium is independent of every other, and
therefore the addition of Hb cannot, per se, alter the
magnesium binding ATP equilibrium, the observed chemical shift is not
independent because it intrinsically reflects a weighted average of
all species present. Therefore the effect of Hb binding on
the observed chemical shifts of both DPG and ATP must be taken into
account. This can be achieved, to a first approximation, by assuming
that chemical shifts did not change when metabolite species bound to
Hb. This is true within a 5% error in oxygenated erythrocytes (2, 23). Simultaneous equations were then formulated which included the effect
that Hb binding had on the equilibria for ATP and DPG and hence on the
overall observed chemical shifts (Equations 10 and 11 and Appendix II).
These equations also required the binding constants for Hb binding to
DPG, ATP, and MgATP. There are two generally accepted sets of constants
(2), which largely agree except on the value of MgATP binding to Hb.
This affected the positions of the equilibria to a different extent as
illustrated in Fig. 6, a and
b) for the analysis of pH and
[Mg2+]free with a total ATP of 2 mM, a total DPG of 5 mM, and a total Hb of 7 mM.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of allowing Hb binding to ATP, MgATP,
and DPG on the theoretical chemical shift -ATP
(a) and 3P-DPG (b), with no Hb
(line), with 2 mM ATP, 5 mM
DPG, and 7 mM Hb and using equilibrium constants from
either Gupta et al. (2) (longer
dashes) or Berger et al. (36)
(shorter dashes).
|
|
This difference led to discrepancies in the calculated values of
pHi and [Mg2+]free. For
comparison, for normal blood, pH, and
[Mg2+]free were determined to be 7.23 ± 0.01 and 0.41 ± 0.04 mM, respectively, using
Berger's constants (36), but 7.25 ± 0.01 and 0.21 ± 0.03 mM using those of Gupta et al. (2). The analysis
presented under "Results" used Berger's constants because errors
may be associated with the methodology (23) used by Gupta
(16).
Effect of K+ and Hb--
For a complete description of
the erythrocyte, the effects of both K+ and Hb should be
taken into account. However, once K+ is specified in the
magnesium-ATP equilibrium, it also needs to be specified in the ATP-Hb
equilibrium. Both Berger (36) and Gupta (2) measured apparent Hb
binding constants using a physiological [K+], and
therefore there are no data available on binding between KATP/KHATP and
Hb. However, if realistic binding constants were estimated such that
the overall binding of "ATP" (ATPfree, HATP, KATP,
KHATP) to Hb remained equal to that measured by Berger, a realistic
possible adjustment to the theoretical equations can be made. Including
all effects of both K+ and Hb, this provided a complete
model of erythrocyte conditions and led to an estimation of pH and
[Mg2+]free in normal red blood cells of 7.20 and 0.41 mM, respectively (Table IV). Although this model
included estimated values for some binding constants, it can be partly
verified by summing all MgX species to find the model
prediction for erythrocyte total magnesium. This was calculated to be
3.1 mM, which is ~90% of that found experimentally.
However, the model does not include the low affinity binding of
Mg2+ to Hb, which, it has been suggested, can account for
the remaining 10% (49). Because Mg2+ does not compete with
ATP and DPG in binding Hb, this factor did not significantly change the
analysis for [Mg2+]free.
Comparisons with Previous Methods--
In the most common analysis
of NMR spectra to yield [Mg2+]free (16, 48,
50), ATP and MgATP end points and an
apparent dissociation constant are determined from in vitro
solutions. It is then assumed that pHi is 7.2.
|
(Eq. 12)
|
Following this procedure, using end points determined here and
assuming K(app)dMgATP = 38 µM (51), [Mg2+]free was
calculated to be 0.24 ± 0.02 and 0.16 ± 0.02 mM
for normal and sickle cells, respectively, significantly different from
the values of 0.41 ± 0.03 and 0.32 ± 0.05 mM
found in this work (Table V). Also, a
comparison was made with values calculated using the original technique
(16), where pHi is, again, assumed to be 7.2, but Hb
interactions are included. This also leads to significantly different
values.
Use of Explicit Constants for the Generation of in Vitro
Solutions--
Solutions are often required in experimental practice
to mimic the conditions found in vivo. These frequently
require an accurate [Mg2+]free in
ATP-containing solutions, but all too often this is calculated using
equilibrium constants that are inappropriate for the conditions used.
This is partly because of constants being quoted as apparent ones, thus
making it difficult to adjust them over a range of conditions. However,
in this work, explicit constants have been determined which readily
allow the generation of a specific [Mg2+]free
in an ATP-containing solution over any range of pH, potassium, ATP,
DPG, Hb, temperature, and ionic strength. Furthermore, this technique
can be used in other cell types if a replacement peak chemical shift is
used instead of DPG, ideally Pi.
Normal versus Sickle Red Blood Cells--
We went on to compare
normal red cells with those from sickle patients. We found that well
oxygenated sickle cells had significantly lower
[Mg2+]free and pHi than normal
red cells but unchanged [ATP]. Our results agree well with the
seminal study by Ortiz and co-workers (40), conducted using the null
point (A23187) method. Thus, values for [DPG],
[Mg2+]free, and MgT in normal red
cells were very similar in the two studies. In both studies, oxygenated
sickle cells had high [DPG], low
[Mg2+]free, and unchanged MgT. A
reduction in [Mg2+]free in sickle cells,
compared with normal cells, could result from an increased buffering
capacity for magnesium because of high [DPG], concomitant with
unchanged [ATP]. We also found similar results in our oxygenated
dense (density > 1.099 g/ml) sickle cell fraction. By contrast,
in their dense fraction (density > 1.118 g/ml), Ortiz et
al. (40) reported an increased
[Mg2+]free and decreased MgT.
This elevation in [Mg2+]free was markedly
exacerbated on deoxygenation, reversing the usual inward magnesium
concentration gradient and providing a mechanism for the magnesium
depletion that they observed in this fraction. The difference in
oxygenated dense cells between the two studies could be attributed to
the difference in the densities chosen for cell fractionation and/or a
difference in magnesium buffering. Although the blood samples were
gassed with 95% O2 to produce a PO2
>150 mm Hg, it is possible that the dense sickle cells were not fully
oxygenated, causing sickle Hb (Hb S) to polymerize (52). To our
knowledge, there are no constants available for binding of metabolites
to Hb polymer, but polymerization would alter
[Mg2+]free estimated using our method and may
explain the low [Mg2+]free in the dense cell fraction.
We found that the pHi of whole sickle blood was 0.10 pH
unit more acidic than that of normal red cells, with a pHi
of 7.10, in agreement with previous NMR studies of buffer-washed red
cells (24). However, at the same PCO2, sickle
blood pHex was also significantly more acidic, by 0.07 pH
unit, than normal.
Low [Mg2+]free and low pH will both activate
KCC1 (53), which may partially explain the high activity of this
transporter in sickle cells. Cell shrinkage, perhaps via overactivity
of KCC1, remains the principal hazard in irreversible sickling. For a
patient with sickle cell anemia in a steady state, the percentage of
red blood cells that are irreversibly sickled is about 15%. With a hematocrit of 20%, this corresponds to 3% of total blood volume. Therefore, although it is important to fractionate cells and analyze the dense cell fraction to understand the mechanisms underlying cell
sickling, it is clinically important to analyze whole sickle blood,
using considerably smaller volumes, to assess the in vivo state of the majority of red blood cells in an effort to prevent sickling.
In summary, we have modeled the observed chemical shift of -ATP and
3P-DPG over a wide range of pH and [Mg2+]free
using appropriate theoretical equations. These equations included
contributions to the overall chemical shift from all possible
intermediates present in solution and represented the multiple
equilibria formed by the interactions among H+,
Mg2+, K+, ATP4 , and
DPG5 . An adjustment for Hb binding was made to the
equations to allow a new, more complete, determination of intracellular
pH and [Mg2+]free using 31P NMR
spectroscopic analysis of red blood cells. Thus, pHi and [Mg2+]free were determined in whole,
oxygenated normal and sickle blood, with pHex,
[Mg]T, ATP, and DPG concentrations. The pHi,
pHex, and [Mg2+]free were
significantly lower in sickle cells, whereas [DPG] was significantly
higher, with no changes in [ATP].
 |
ACKNOWLEDGEMENTS |
We thank Nurse Sue Stevens for kind
assistance with the blood samples, Asif Khan for help with the
preparation of the Stractan gradients, and Drs. V. L. Lew and J. F.
Gibson for invaluable advice.
 |
FOOTNOTES |
*
This work was supported in part by the British Heart
Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at www.jbc.org)
contains Appendices I and II.
Recipient of a Ph.D. studentship from the Biotechnology and
Biological Sciences Research Council.
§
Supported by the Australian National Health and Medical Research Council.
**
To whom correspondence should be addressed. Tel.:
44-1865-275-255; Fax: 44-1865-275-259; E-mail:
Kieran.Clarke@bioch.ox.ac.uk.
Published, JBC Papers in Press, September 23, 2002, DOI 10.1074/jbc.M207551200
2
V. L. Lew, personal communication.
 |
ABBREVIATIONS |
The abbreviations used are:
[Mg2+]free, concentration of unbound
magnesium;
-ATP, phosphate group at the position of ATP;
DPG, 2,3-diphosphoglycerate;
  -MgATP and
  -ATP, chemical shift difference between - and
-phosphorous nuclei of ATP when bound to magnesium and unbound,
respectively;
obs, observed chemical shift;
K(app)bMgATP , apparent MgATP binding
constant;
K(app)dMgATP, apparent
dissociation constant for MgATP;
LW, half-peak line width;
MgT, total concentration of magnesium;
2P- and 3P-DPG, phosphate group on the second and third carbon atom of DPG,
respectively.
 |
REFERENCES |
| 1.
|
Gerber, G.,
Preissler, H.,
Heinrich, R.,
and Rapport, S. M.
(1974)
Eur. J. Biochem.
45,
39-52[Medline]
[Order article via Infotrieve]
|
| 2.
|
Gupta, R. K.,
Benovic, J. L.,
and Rose, Z. B.
(1978)
J. Biol. Chem.
253,
6165-6171[Free Full Text]
|
| 3.
|
Lawson, J. W. R.,
and Veech, R. L.
(1979)
J. Biol. Chem.
254,
6528-6537[Abstract/Free Full Text]
|
| 4.
|
Stephenson, E. W.,
and Podolsky, R. J.
(1977)
J. Gen. Physiol.
69,
1-16[Abstract/Free Full Text]
|
| 5.
|
Flatman, P. W.
(1988)
J. Physiol. (Lond.)
397,
471-487[Abstract/Free Full Text]
|
| 6.
|
Resnick, L. M.,
Gupta, R. K.,
Gruenspan, H.,
Alderman, M. H.,
and Laragh, J. H.
(1990)
Am. J. Hypertens.
3,
373-379[Medline]
[Order article via Infotrieve]
|
| 7.
|
Duley, L.
(2002)
Lancet
359,
1877-1890[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
De Franceschi, L.,
Bachir, D.,
Galacteros, F.,
Tchernia, G.,
Cynober, T.,
Alper, S.,
Platt, O.,
Beuzard, Y.,
and Brugnara, C.
(1997)
J. Clin. Invest.
100,
1847-1852[Medline]
[Order article via Infotrieve]
|
| 9.
|
Noguchi, C. T.,
and Schechter, A. N.
(1981)
Blood
58,
1057-1068[Free Full Text]
|
| 10.
|
Ellory, J. C.,
Flatman, P. S.,
and Stewart, G. W.
(1983)
J. Physiol. (Lond.)
340,
1-17[Abstract/Free Full Text]
|
| 11.
|
Brugnara, C.
(1989)
Ann. N. Y. Acad. Sci.
565,
96-103[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Scarpa, A.
(1982)
Tech. Cell. Physiol.
127,
1-40
|
| 13.
|
Zhang, W.,
Truttmann, A. C.,
Luthi, D.,
and McGuigan, J. A. S.
(1997)
Anal. Biochem.
251,
246-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Rink, T. J.,
Tsien, R. Y.,
and Pozzan, T.
(1982)
J. Cell Biol.
95,
189-196[Abstract/Free Full Text]
|
| 15.
|
Flatman, P. W.,
and Lew, V. L.
(1977)
Nature
267,
360-362[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Gupta, R. K.,
Benovic, J. L.,
and Rose, Z. B.
(1978)
J. Biol. Chem.
253,
6172-6176[Abstract/Free Full Text]
|
| 17.
|
London, R. E.
(1991)
Annu. Rev. Physiol.
53,
241-258[Medline]
[Order article via Infotrieve]
|
| 18.
|
Geven, W. B.,
Vogels Mentink, G. M.,
Willems, J. L.,
von Os, C. H.,
Hilbers, C. W.,
Joordens, J. J.,
Rijksen, G.,
and Monnens, L. A.
(1991)
Clin. Chem.
37,
2076-2080[Abstract/Free Full Text]
|
| 19.
|
Ouwerkerk, R.,
Van Echteld, C. J. A.,
Staal, G. E. J.,
and Rijksen, G.
(1989)
Biochim. Biophys. Acta
1010,
294-303[Medline]
[Order article via Infotrieve]
|
| 20.
|
Flatman, P. W.
(1980)
J. Physiol. (Lond.)
300,
19-30[Abstract/Free Full Text]
|
| 21.
|
Moon, R. B.,
and Richards, J. H.
(1973)
J. Biol. Chem.
248,
7276-7278[Abstract/Free Full Text]
|
| 22.
|
Lam, Y.-F.,
Allison, K.,
and Ho, C.
(1979)
Blood
54,
196-209[Abstract/Free Full Text]
|
| 23.
|
Mulquiney, P. J.,
and Kuchel, P. W.
(1997)
NMR Biomed.
10,
129-137[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Tehrani, A. Y.,
Lam, Y.-F.,
Allison, K.,
and Ho, C.
(1982)
Blood Cells
8,
245-261[Medline]
[Order article via Infotrieve]
|
| 25.
|
Marjanovic, M.,
Gregory, C.,
Ghosh, P.,
Willis, J. S.,
and Dawson, M. J.
(1993)
J. Physiol. (Lond.)
470,
559-574[Abstract/Free Full Text]
|
| 26.
|
Garfinkel, L.,
and Garfinkel, D.
(1984)
Biochemistry
23,
3547-3552[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Golding, E. M.,
and Golding, R. M.
(1995)
Mag. Reson. Med.
33,
467-474[Medline]
[Order article via Infotrieve]
|
| 28.
|
Goldberg, R. N.,
and Tewari, Y. B.
(1991)
Biochem. J.
40,
241-261
|
| 29.
|
Mosher, T. J.,
Williams, G. D.,
Doumen, C.,
LaNoue, K. F.,
and Smith, M. B.
(1992)
Mag. Reson. Med.
24,
163-169[Medline]
[Order article via Infotrieve]
|
| 30.
|
Roberts, J. K.,
Wade-Jardetsky, N.,
and Jardetzky, O.
(1981)
Biochem. J.
20,
5389-5394
|
| 31.
|
Williams, G. D.,
Mosher, T. J.,
and Smith, M. B.
(1993)
Anal. Biochem.
214,
458-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Willcocks, J. P.,
Veech, R. L.,
Ellory, J. C.,
Clarke, K.,
and Radda, G. K.
(1999)
Biophys. J.
76,
233[Medline]
[Order article via Infotrieve] (abstr.)
|
| 33.
|
Willcocks, J. P.,
Veech, R. L.,
Ellory, J. C.,
and Clarke, K.
(2000)
Biophys. J.
78,
449 (abstr.)
|
| 34.
|
Clarke, K.,
Kashiwaya, Y.,
King, M. T.,
Gates, D.,
Keon, A.,
Cross, H. R.,
Radda, G. K.,
and Veech, R. L.
(1996)
J. Biol. Chem.
271,
21142-21150[Abstract/Free Full Text]
|
| 35.
|
Veech, R. L.,
Gates, D. N.,
Crutchfield, C.,
Gitomer, W. L.,
Kashiwaya, Y.,
King, M. T.,
and Wondergem, R.
(1994)
Alcohol Clin. Exp. Res.
18,
1040-1056[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Berger, H.,
Janig, G.-R.,
Gerber, G.,
Ruckpaul, K.,
and Rapport, S. M.
(1973)
Eur. J. Biochem.
38,
553-562[Medline]
[Order article via Infotrieve]
|
| 37.
|
Mulquiney, P. J.,
and Kuchel, P. W.
(1997)
Eur. J. Biochem.
245,
71-83[Medline]
[Order article via Infotrieve]
|
| 38.
|
Werner, A.,
and Heinrich, R.
(1985)
Biomed. Biochim. Acta
44,
185-212[Medline]
[Order article via Infotrieve]
|
| 39.
|
Kaperonis, A. A.,
Bertles, J. F.,
and Chien, S.
(1979)
Br. J. Haematol.
43,
391-400[Medline]
[Order article via Infotrieve]
|
| 40.
|
Ortiz, O. E.,
Lew, V. L.,
and Bookchin, R. M.
(1990)
J. Physiol. (Lond.)
427,
211-226[Abstract/Free Full Text]
|
| 41.
|
Corash, L. M.,
Piomelli, S.,
Chen, H. C.,
Seaman, C.,
and Gross, E.
(1974)
J. Lab. Clin. Med.
84,
147-151[Medline]
[Order article via Infotrieve]
|
| 42.
|
Ortiz, O. E.,
Lew, V. L.,
and Bookchin, R. M.
(1986)
Blood.
67,
710-715[Abstract/Free Full Text]
|
| 43.
|
Jaeger, B. R.,
Goehring, P.,
Schirmer, J.,
Uhrig, S.,
Lohse, P.,
Kreuzer, E.,
Reichart, B.,
and Seidel, D.
(2001)
Ther. Apher.
5,
252-259[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Vasavada, K. V.,
Ray, B. D.,
and Nageswara Rao, B. D.
(1984)
J. Inorg. Biochem.
21,
323-335[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Ramirez, F.,
and Marecek, J. F.
(1980)
Biochim. Biophys. Acta
589,
21-29[Medline]
[Order article via Infotrieve]
|
| 46.
|
Pecoraro, V. L.,
Hermes, J. D.,
and Cleland, W. W.
(1984)
Biochem. J.
23,
5262-5271
|
| 47.
|
Gupta, R. K.,
and Moore, R. D.
(1980)
J. Biol. Chem.
255,
3987-3993[Free Full Text]
|
| 48.
|
Gupta, R. K.,
Gupta, P.,
Yushok, W. D.,
and Rose, Z. B.
(1983)
Physiol. Chem. Phys. Med. NMR
15,
265-280[Medline]
[Order article via Infotrieve]
|
| 49.
|
Raftos, J. E.,
Lew, V. L.,
and Flatman, P. W.
(1999)
Eur. J. Biochem.
263,
635-645[Medline]
[Order article via Infotrieve]
|
| 50.
|
Altura, B. M.,
Gebrewold, A.,
Altura, B. T.,
and Gupta, R. K.
(1995)
Alcohol
12,
131-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Gupta, R. K.,
Gupta, P.,
Yushok, W. D.,
and Rose, Z. B.
(1983)
Biochem. Biophys. Res. Commun.
117,
210-216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Noguchi, C. T.,
Torchia, D. A.,
and Schechter, A. N.
(1983)
J. Clin. Invest.
72,
846-852[Medline]
[Order article via Infotrieve]
|
| 53.
|
De Franceschi, L.,
Bachir, D.,
Galacteros, F.,
Tchernia, G.,
Cynober, T.,
Neuberg, D.,
Beuzard, Y.,
and Brugnara, C.
(2000)
Br. J. Haematol.
108,
284-289[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Achilles, W.,
Cumme, G. A.,
and Hoppe, H.
(1972)
Acta Biol. Med. Ger.
29,
531-538[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|